ORPHA:79153
Idiopathic trachyonychia
Publications
155
61.2th percentile
Trials
0
Interventional, condition-specific
Researchers
551
Distinct authors in sample
Gene link
FZD6
Definitive
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare isolated nail anomaly characterized by brittle, thin, rough, opaque appearing nails with excessive longitudinal ridging. In a less severe form, the nails retain their luster and present with superficial ridging and multiple small geometric pits. In both varieties, superficial scaling of the nail plate and hyperkeratosis of the cuticles, as well as koilonychia and onychoschizia are observed. Any number of nails may be affected, and fingernails are more often affected than toenails. Spontaneous improvement of the condition may occur.
How rare: How common this is has not been clearly measured.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0008060
- MeSH:C562907
- OMIM:161050
- UMLS:C0406443
Additional Mondo synonyms (8)
FZD6 inherited isolated nail anomaly · inherited isolated nail anomaly caused by mutation in FZD6 · nail disorder, nonsyndromic congenital, type 10 · nonsyndromic congenital nail disorder 10 · nonsyndromic congenital nail disorder type 1 · nonsyndromic congenital nail disorder type 10 · onychodystrophy totalis · twenty-nail dystrophy
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.
- Gene identifiedPresent
Definitive — FZD6
- LiteraturePresent
155 matched papers (74 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (FZD6).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
155
155 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
155 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
74 in the last 10 years · high confidence · 61.2th percentile (publications denominator)
Phrase hits: 155 · MeSH hits: 4
Who's working on it?
551
Distinct author names in 155 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Grover C7 papers · 2025
Department of Dermatology, Maulana Azad Medical College and Associated Hospitals, 11/15 Nehru Nagar, New Delhi 110065, India. chander-groverkubba@rediffmail.com
Papers in Europe PMC - 02Bansal S4 papers · 2025
Department of Dermatology and STD, VMMC and Safdarjung Hospital, New Delhi, India.
Papers in Europe PMC - 03Khandpur S4 papers · 2007
Department of Dermatology and Venereology, Maulana Azad Medical College, New Delhi, India.
Papers in Europe PMC - 04Nanda S4 papers · 2025
Department of Dermatology, Max Hospital, New Delhi, India.
Papers in Europe PMC - 05Piraccini BM4 papers · 2026
Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Papers in Europe PMC - 06Reddy BS4 papers · 2005Papers in Europe PMC
- 07Sehgal VN4 papers · 2018
Dermato-Venereology (Skin/VD) Centre, Sehgal Nursing Home, Panchati, Azadpur, Delhi, India. drsehgal@ndf.vsnl.net.in.
Papers in Europe PMC - 08
- 09Mun JH3 papers · 2021
Department of Dermatology, Pusan National University Yangsan Hospital, Yangsan, Korea.
Papers in Europe PMC - 10Starace M3 papers · 2026
Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
high confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Idiopathic trachyonychia" OR "FZD6 inherited isolated nail anomaly" OR "inherited isolated nail anomaly caused by mutation in FZD6" OR "nail disorder, nonsyndromic congenital, type 10" OR "nonsyndromic congenital nail disorder 10" OR "nonsyndromic congenital nail disorder type 1" OR "nonsyndromic congenital nail disorder type 10" OR "onychodystrophy totalis" OR "twenty-nail dystrophy"
MeSH descriptor terms unioned into the query: Twenty-Nail Dystrophy
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Idiopathic trachyonychia" OR "FZD6 inherited isolated nail anomaly" OR "inherited isolated nail anomaly caused by mutation in FZD6" OR "nail disorder, nonsyndromic congenital, type 10" OR "nonsyndromic congenital nail disorder 10" OR "nonsyndromic congenital nail disorder type 1" OR "nonsyndromic congenital nail disorder type 10" OR "onychodystrophy totalis" OR "twenty-nail dystrophy" OR "FZD6"
Recall-expansion terms: FZD6
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase, mesh, recall-expansion; with hits: phrase, mesh
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T02:04:41.543Z